Combination of doses, better than monotherapy for pulmonary hypertension

Published Date: 08 Mar 2023

People with hypertension (high blood pressure in the arteries that supply the lungs, also known as PAH) have up to a two-fold reduction in pulmonary vascular resistance (PVR) when taking PAH.

Read Full News

Latest News

Europe Risks Falling Behind in Medicine Race, Roche CEO

Europe risks falling behind the US and China in pharma innovation because of bureaucracy and government policies threatening ⁠jobs, Roche CEO Thomas Schinecker warns.

US Health Regulators to Speed Up Medicare Device Coverage

U.S. health regulators announced a new program to speed up Medicare coverage for certain medical devices on ⁠Thursday, saying it would cut reimbursement timelines to as...

Germany Risks Missing Out on New Drugs, AstraZeneca CEO Says

AstraZeneca's CEO said Germany risks missing out on new drugs that ⁠the drugmaker plans to launch if the nation sticks with plans to keep pharmaceutical spending in check.

U.S. to Ask States to Revalidate "high-risk" Medicaid Providers

Mehmet Oz, who heads the agency that runs the U.S. Medicare and ⁠Medicaid healthcare programs, said on Tuesday the Trump administration plans to ask all ⁠50 states to...

US FDA Warns Medline Over Defective Heart Procedure Syringes

The U.S. Food and Drug Administration has told medical device maker Medline that its syringes used in heart procedures ⁠are defective and warned the company of penal actions.

Swiss Industry Body Says US Tariffs on Pharmaceuticals Will Harm Patients

U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, ⁠supply chains and ultimately will harm patients, Switzerland's...

Todays Updates

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

Todays Updates

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

Latest News

Europe risks falling behind the US and China in pharma innovation because of bureaucracy and government policies threatening ⁠jobs, Roche CEO Thomas Schinecker warns.

U.S. health regulators announced a new program to speed up Medicare coverage for certain medical devices on ⁠Thursday, saying it would cut reimbursement timelines to as...

AstraZeneca's CEO said Germany risks missing out on new drugs that ⁠the drugmaker plans to launch if the nation sticks with plans to keep pharmaceutical spending in check.

Mehmet Oz, who heads the agency that runs the U.S. Medicare and ⁠Medicaid healthcare programs, said on Tuesday the Trump administration plans to ask all ⁠50 states to...

The U.S. Food and Drug Administration has told medical device maker Medline that its syringes used in heart procedures ⁠are defective and warned the company of penal actions.

U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, ⁠supply chains and ultimately will harm patients, Switzerland's...

News All Time

Tirzepatide may only temporarily suppress brain 'food noise' activity

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" ...

Supercomputer simulation is changing how we study the brain

Harnessing the muscle of one of the world's fastest supercomputers, researchers have built one of the largest and most detailed biophysically realistic brain simulations of an animal ever.

AI tool creates digital twins of patients to predict their future health

A new artificial intelligence tool that can create virtual representations of patients and predict individual health trajectories has been hailed a potential gamechanger for the clinical trial sector.

New tool predicts graft failure after kidney transplant

Researchers at The Johns Hopkins Medicine say they have developed a new electronic medical records-based tool that should help doctors predict which patients are most at risk of losing a transplanted kidney graft.

How are patients using health care chatbots? Study finds some 'eye-openers'

A health care chatbot can be a patient's first point of contact for some sensitive conversations from mental health to billing, a new CU Anschutz study has found.

New study reveals high rates of fabricated and inaccurate citations in LLM-generated mental health research

A new study published in the journal JMIR Mental Health by JMIR Publications highlights a critical risk in the growing use of Large Language Models (LLMs) like GPT-4o by researchers: the frequent fabrication and inaccuracy ...

A unified model of memory and perception: How Hebbian learning explains our recall of past events

A collaboration between SISSA's Physics and Neuroscience groups has taken a step forward in understanding how memories are stored and retrieved in the brain. The study, recently published in Neuron, shows that distinct perceptual ...

Malaria rapid diagnostic test 'not fit for purpose,' international study claims

An international study published in the Malaria Journal claims that a widely used test for detecting malaria is delivering too many inaccurate false-negative results and is "not fit for purpose."

Reaching the unreachable: Endoscopy technique opens route to deep lung tumors

Researchers at the University of Osaka have engineered a novel technique, balloon-assisted bronchoscope delivery (BDBD), to guide endoscopes to small, early-stage lung cancers hidden deep within the periphery of the lungs.

Healing the heart after a heart attack with a biodegradable patch

A new patch developed by Texas A&M University researcher Dr. Ke Huang may offer a way to help the heart heal after a heart attack. The patch uses a unique microneedle system to deliver a therapeutic molecule directly to damaged ...

Would you put period blood on your face? What science says about 'menstrual masking'

In the ever-evolving world of beauty trends, few have sparked as much debate—and discomfort—as "menstrual masking." This is the practice of applying menstrual blood to the skin, usually the face, as a form of DIY skincare.

Ovarian tissue preservation enables future fertility for young woman with cancer

In patients of reproductive age who have cancer, fertility preservation for potential children in the future should be a high priority. A practice article published in the Canadian Medical Association Journal describes the ...

Simple test brings clarity and hope for families with inherited neuropathy

A new, inexpensive urine test that measures two sugar alcohols, sorbitol and xylitol, is making it easier, faster, and far less expensive to identify a common inherited nerve disorder called SORD-related neuropathy. The test, ...

One of the world's oldest blood pressure drugs may also halt aggressive brain tumor growth

A Penn-led team has revealed how hydralazine, one of the world's oldest blood pressure drugs and a mainstay treatment for preeclampsia, works at the molecular level. In doing so, they made a surprising discovery—it can ...

From body fat to bone, experiment offers hope for 'gentle' repair of fractures

Japanese researchers are testing a surprising, minimally invasive way to repair spine fractures.

At some doctors' offices, AI is listening in the exam room

Bracken Babula starts patient visits these days by closing the exam room door and asking if they mind him recording their conversation. He hits a button on his mobile phone, checks that it is recording, and sits back in his ...

Recommended News For You

Detecting pancreatic cancer through changes in body composition and metabolism

Formaldehyde releasers found in common personal care products used especially by Black and Latina women

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

A three-quarters reduction in the risk of prostate cancer is associated with an annual increase in cardiorespiratory fitness of more than three percent.

Treating advanced prostate cancer

Metastatic breast cancer can be effectively treated with cyclical estrogen and anti-estrogen therapy.

Recommended Articles For You

Unlocking the Potential of CPK Levels: How to Maximize Your Health Benefits 

New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma  

Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer 

Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Single-dose radiation before surgery can eradicate breast cancer

2.

Never in a million years did I think I'd have to limit my chemotherapy.

3.

Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma

4.

Virtual Reality Travel Reduces Cancer Pain.

5.

The Truth About Apple AirPods

1.

All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment

2.

A Comprehensive Guide To Understanding Plasma Osmolality

3.

The Rise of Immunotherapy: New Advances in Cancer Treatment

4.

Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer

5.

Unveiling the Secrets of Early Cancer: Emerging Strategies to Decipher Its Biology

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

2.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

5.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot